Amoxycillin-clavulanic acid combination in bronchopulmonary infection due to beta-lactamase-producing Branhamella catarrhalis. Preliminary report

Drugs. 1986:31 Suppl 3:113-4. doi: 10.2165/00003495-198600313-00024.

Abstract

Since 1978 we have taken an interest in lower respiratory tract infections associated with Branhamella catarrhalis in Christchurch, New Zealand. In a preliminary trial, 20 patients with bronchopulmonary infection caused by beta-lactamase-producing B. catarrhalis were treated with a combination tablet of amoxycillin 500 mg and clavulanic acid 125 mg ('Augmentin') 3 times daily for 5 days. Sputum cultures were negative for B. catarrhalis within 3 days in all patients. Two of 7 patients whose sputum cultures were positive for this organism at a review 2 to 4 weeks later were successfully treated with a further course of amoxycillin/clavulanic acid.

Publication types

  • Clinical Trial

MeSH terms

  • Amoxicillin / administration & dosage
  • Amoxicillin / therapeutic use*
  • Clavulanic Acid
  • Clavulanic Acids / administration & dosage
  • Clavulanic Acids / therapeutic use*
  • Clinical Trials as Topic
  • Drug Combinations
  • Humans
  • Neisseriaceae / enzymology*
  • New Zealand
  • Penicillin Resistance
  • Respiratory Tract Infections / drug therapy*
  • Respiratory Tract Infections / microbiology
  • beta-Lactamases / metabolism*

Substances

  • Clavulanic Acids
  • Drug Combinations
  • Clavulanic Acid
  • Amoxicillin
  • beta-Lactamases